IDO1 and schizophrenia: The present study is a 6-week, randomized, double-blind, and placebo-controlled trial to investigate the expression of IDO in serum blood of first-episode drug-naive schizophrenia patients and to explore the correlation between IDO and various inflammatory cytokines by using the COX2 inhibitor celecoxib.